Best Biologics / mAb CDMOs in Asia
· updated as new inspection, certificate, and trial data enters the platform
23
CDMOs tracked
9
Fully scored
9
With FDA records
25
FDA inspections
21
EMA/MHRA GMP certs
2
Warning letters
Biologics CDMOs manufacture monoclonal antibodies, fusion proteins, and other large molecules in mammalian (typically CHO) cell culture. It is the largest and most mature segment of contract manufacturing, spanning early clinical supply through multi-thousand-litre commercial production.
Selecting a biologics CDMO turns on bioreactor scale and modality fit (mAb, bispecific, fusion protein), titer and cell-line strategy, fill-finish, and — above all — a clean regulatory record at commercial scale. The rankings below score each CDMO on FDA inspection history, EMA/MHRA GMP certification, clinical-program activity, and capacity.
FDA inspection outcomes across these CDMOs: 12 NAI (no action), 13 VAI (voluntary action), 0 OAI (official action). Leading inspection & GMP sites: India (18), UNITED KINGDOM (10), INDIA (7), United States (4), UNITED STATES (2).
Last updated 2026-10-30. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
| # | CDMO | Signal Score | Quality | FDA · GMP | Capacity | Programs |
|---|---|---|---|---|---|---|
| 1 |
AJ
Ajinomoto Bio-Pharma Services
San Diego, CA · Osaka, JP
|
83.5 | 100.0 | 0 insp · 1 GMP | — | 0 programs |
| 2 |
PR
Piramal Pharma Solutions
Lexington, KY · Riverview, MI · Ahmedabad, IN
|
83.5 | 95.6 | 7 insp · 15 GMP | — | 0 programs |
| 3 |
LB
Lotte Biologics
Incheon, KR · Syracuse, NY
Hiring · 8 open roles
|
81.6 | 100.0 | 2 insp · 0 GMP | — | 0 programs |
| 4 |
SG
Syngene International
Bengaluru, India
Hiring · 6 open roles
|
80.3 | 100.0 | 3 insp · 0 GMP | — | 0 programs |
| 5 |
SI
Simtra BioPharma Solutions
Bloomington, IN · Halle, DE
Hiring · 106 open roles
|
65.7 | 73.3 | 0 insp · 1 GMP | — | 0 programs |
| 6 |
PBI
ProBio
Pennington, NJ · Nanjing, CN
|
64.0 | — | — | — | 0 programs |
| 7 |
AU
Aurigene Pharmaceutical Services
Hyderabad, India
|
63.0 | — | — | — | 0 programs |
| 8 |
SS
Singota Solutions
Bloomington, IN
|
59.0 | — | — | — | 0 programs |
| 9 |
IC
INCOG BioPharma Services
Fishers, IN
|
56.5 | — | — | — | 0 programs |
| — |
Anthem Biosciences
India
|
Profiled | — | 1 insp · 0 GMP | — | 0 programs |
| — |
Shilpa Medicare
India (registered sites)
|
Profiled | — | 5 insp · 1 GMP | — | 0 programs |
| — |
Aragen Life Sciences
India
|
Profiled | — | 2 insp · 0 GMP | — | 0 programs |
| — |
BE Biosol
India
|
Profiled | — | 0 insp · 1 GMP | — | 0 programs |
| — |
Celltrion Pharm
South Korea
|
Profiled | — | 1 insp · 0 GMP | — | 0 programs |
| — |
OneSource Specialty Pharma
India
|
Profiled | — | 3 insp · 0 GMP | — | 0 programs |
| — |
Cadila Pharmaceuticals (CDMO-CMO)
Ahmedabad, Gujarat, India
|
Profiled | — | 0 insp · 1 GMP | — | 0 programs |
| — |
Celltrion (CMO/CDMO)
Incheon, South Korea
|
Profiled | — | 0 insp · 1 GMP | — | 0 programs |
| — |
Prestige Biologics
Osong, Cheongju, South Korea
|
Profiled | — | — | — | 0 programs |
| — |
MicroBiopharm Japan
Tokyo, Japan
|
Profiled | — | 1 insp · 0 GMP | — | 0 programs |
| — |
BTGEN
Incheon, South Korea
|
Profiled | — | — | — | 0 programs |
| — |
Binex
Busan, South Korea
|
Profiled | — | — | — | 0 programs |
| — |
Daewoong Bio
Hwaseong, Gyeonggi, South Korea
|
Profiled | — | — | — | 0 programs |
| — |
Hanmi Pharm
Seoul, South Korea
|
Profiled | — | — | — | 0 programs |
What to evaluate in a Biologics / mAb CDMO
Scale & bioreactor fit
Match validated bioreactor scale (from a few hundred litres clinical to 2,000L+ commercial) and single-use vs stainless to your dose and indication. Confirm titer expectations for your construct.
Cell line & process development
Ask whether the CDMO offers its own expression platform/cell line or works from yours, and how process development and tech transfer are handled.
Regulatory track record
Biologics programs heading to BLA/MAA need a strong commercial-scale inspection history. Cross-check FDA 483s, warning letters, and EMA/MHRA GMP coverage — all shown above.
Drug substance to drug product
Confirm whether the CDMO covers fill-finish and formulation in-house or coordinates a separate site, which affects timelines and comparability.
Regulatory landscape across PMDA (Japan), NMPA (China), MFDS (South Korea)
Asian biopharma manufacturing spans multiple national regulators. PMDA (Japan) is generally regarded as one of the most stringent in Asia, with GMP requirements broadly aligned with FDA and EMA. NMPA (China) has substantially strengthened its GMP framework over the past decade, and Chinese CDMOs increasingly hold FDA and EMA certifications alongside NMPA registration. MFDS (South Korea) certification is standard for Korean CDMOs. For sponsors supplying US or EU markets, the qualifying signal for an Asian CDMO is typically FDA and EMA inspection history on the specific facility — which the Signal Score's Quality Compliance pillar captures directly.
Which Asian CDMOs cover FDA (US) and EMA/MHRA (Europe) regulatory geographies?
Asian CDMOs with US FDA and European EMA/MHRA inspection history are qualified to supply global markets; those without cross-jurisdictional inspection posture are typically limited to their home-market regulatory scope. The Signal Score's Quality Compliance pillar includes FDA + EMA + MHRA data directly, so Asian CDMOs with cross-jurisdictional certification typically rank higher on this pillar than home-market-only competitors. Sponsors evaluating an Asian CDMO for a US or EU program should cross-check with the US region ranking and Europe region ranking — CDMOs appearing across regions have demonstrated multi-jurisdictional posture.
Recent US regulatory events affecting Asian CDMO selection (WuXi 1260H, BioSecure Act considerations)
Asian CDMOs — particularly Chinese-headquartered players — are subject to US regulatory events that affect sponsor risk assessment. The US Department of Defense's 1260H list (which added WuXi AppTec in June 2026) and the BioSecure Act (proposed federal legislation restricting federally-funded research and Medicare/Medicaid drug programs from working with named Chinese biotech companies) are both active considerations. CDMO Signal's platform does not encode US political risk into the Signal Score directly — the composite reflects regulatory quality, operations, financial stability, and capacity signals. Sponsors weighing an Asian CDMO for a US-supplying program should evaluate US regulatory risk separately as a distinct decision layer alongside the Signal Score-based capability assessment.
Biologics / mAb CDMOs — Frequently Asked Questions
Who are the top Biologics / mAb CDMOs?
By CDMO Signal's independent Signal Score, the top-ranked Biologics / mAb CDMOs include Ajinomoto Bio-Pharma Services, Piramal Pharma Solutions, Lotte Biologics. See the full ranked table above — scored on FDA, clinical, financial, and capacity data.
How many Biologics / mAb CDMOs have FDA inspection records?
CDMO Signal tracks 9 Biologics / mAb CDMOs with FDA inspection records and 21 EMA/MHRA GMP certificates across the group.
What should I look for in a biologics CDMO?
Match bioreactor scale and modality (mAb, bispecific, fusion protein) to your program, confirm cell-line and process-development support, and prioritize a clean FDA and EMA/MHRA record at the scale you'll commercialize at.
What is the difference between a biologics CDMO and a cell or gene therapy CDMO?
Biologics CDMOs make large molecules (antibodies, proteins) in bioreactors at litre-to-thousands-of-litre scale. Cell and gene therapy CDMOs make living cells or viral vectors in much smaller, often per-patient batches under different containment and analytics.
Related modalities